Filtered By:
Drug: Clopidogrel
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 1913 results found since Jan 2013.
No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke
CONCLUSIONS: No rebound increase in the risk of ischemic stroke and composite events was found during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke in the CHANCE trial.TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.PMID:35695332 | DOI:10.1080/01616412.2022.2075660
Source: Neurological Research - June 13, 2022 Category: Neurology Authors: Xinmiao Zhang Jing Jing Xingquan Zhao Liping Liu Anxin Wang Yuesong Pan David Wang S Claiborne Johnston Yilong Wang Yongjun Wang Xia Meng Source Type: research
Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research
Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of ticagrelor versus aspirin and clopidogrel for stroke prevention in patients with vascular disease: a systematic review and meta-analysis
Introduction: Currently, it is still controversial to treat stroke with ticagrelor alone. The purpose of our study was to systematically review and analyze the efficacy and safety of ticagrelor on cerebrovascular outcomes in patients with vascular risk factors.
Methods: The PubMed, Cochrane Library, and EMBASE databases were systematically searched using the keywords stroke, ticagrelor, clopidogrel, and aspirin to identify randomized controlled trials (RCT). Primary outcomes included reported stroke, ischemic stroke and complex events; the secondary outcome was hemorrhagic stroke. The safety outcomes included major bleedi...
Source: European Neurology - April 17, 2023 Category: Neurology Source Type: research
Association between post-stroke smoking and stroke recurrence in first-ever ischemic stroke survivors: based on a 10-year prospective cohort
ConclusionsSmoking could elevate the risk of IS recurrence, and IS survivor should be advised to quit or smoke less. Add-on effect of clopidogrel may not exist in smoking strokers taking clopidogrel.
Source: Neurological Sciences - June 8, 2023 Category: Neurology Source Type: research
Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study
ConclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens.Trial Registration NumberChiCTR1900025214.
Source: Cardiovascular Drugs and Therapy - June 13, 2023 Category: Cardiology Source Type: research
